Preparation and in vitro transdermal permeation of cyclosporin A microemulsion papua cream eye patch

doi:10.3969/j.issn.2095-4344.0715

Abstract

Abstract:

BACKGROUND: Immune eye diseases such as hyperthyroidism exophthalmos and uveitis seriously endanger the eye health of patients, which are common and difficult eye diseases. Current treatments for these diseases include oral administration of hormones and immunosuppressive agents, with poor efficacy, recurrent attacks and poor prognosis. Meanwhile, these treatments can induce systemic adverse reactions. Lymphocytes are directly or indirectly involved in these diseases. Therefore, we try to make papua eye patch carrying immunosuppressant, and deliver the drug through the topical use. Cyclosporin A microemulsion targeting lymphocytes can treat or control palpebral lymph nodes involved in the immune eye diseases. It is a topical method rather than the systemic medication, which is targeted and has small doses of drugs. If possible, this treatment can effectively treat immune eye diseases and avoid systemic drug adverse reactions and long-term adverse reactions induced by original drugs.

OBJECTIVE: To study the preparation of cyclosporin A microemulsion papua cream eye patch, and its transdermal absorption characteristics in vitro.

METHODS: Cyclosporine A microemulsion was fully mixed with water-soluble polymer materials at a ratio of 1 mg:1 mL, including sodium polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, gelatin, peach gum, sodium carboxymethylcellulose, hydroxypropylcellulose, and then coated onto the non-woven fabric to prepare Babu cream. Permeability of the Babu cream on the abdominal skin of ICR mice was determined by Franz diffusion cell method. High-performance liquid chromatography was used to detect the concentration of cyclosporine A, and skin irritation and anaphylaxis were also measured.

RESULTS AND CONCLUSION: Cyclosporin A microemulsion papua cream eye patch was successfully prepared with appropriate viscosity, good permeability, good permeability, comfortable application, no skin irritation and allergic reaction. The content of cyclosporine A was 10 mg/tablet, and the concentration was 1 g/L. The concentration of cyclosporine A microemulsion increased with the increase of time, and it had good transdermal effect. This study proved that it is feasible to prepare cyclosporine A microemulsion into papua patch. It has good performance in skin permeability, adhesion and skin comfort.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Key words: Cyclophilins, Immunosuppressive Agents, Immunotoxins, Tissue Engineering

CLC Number:

R318

Chen Min, Xu Li-jiang, Weng Jing-ning, Shangguan Xiao-hui, Yan Jun, Huang Jin-qi, Chen Dan-na. Preparation and in vitro transdermal permeation of cyclosporin A microemulsion papua cream eye patch[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(10): 1553-1558.

Figures/Tables 4

References

[1]Rajaii F, McCoy AN, Smith TJ. Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside. Expert Rev Ophthalmol.2014;9(3):227-234.

[2]Jang SY, Lee KH, Oh JR, et al. Development of Thyroid-Associated Ophthalmopathy in Patients Who Underwent Total Thyroidectomy. Yonsei Med J. 2015;56(5):1389-1394.

[3]Salvi M. Immunotherapy for Graves' ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):409-414.

[4]Kavoussi SC, Giacometti JN, Servat JJ, et al. The relationship between sex and symmetry in thyroid eye disease. Clin Ophthalmol. 2014;8:1295-1300.

[5]居红格,谢建兰,郭新建,等.眼结膜粘膜相关淋巴组织边缘带B细胞淋巴瘤临床病理分析[J].临床与实验病理学杂志, 2014,30(8):840-843.

[6]张庆,邵毅,关晏星,等.标准剂量泼尼松联合谷氨酰胺对I131治疗后Graves眼病的保护作用[J].重庆医学, 2017,46(13):1775-1778.

[7]张袆,张险峰,韩辉,等.中小剂量甲泼尼龙联合甲氨蝶呤与硒酵母对Graves眼病的疗效观察[J].中华内分泌代谢杂志, 2016,32(1):24-26.

[8]唐宇光.甲巯咪唑联合左甲状腺素治疗甲亢性突眼的临床效果分析[J].黑龙江医药,2016,29(2):279-280.

[9]张道武.醋酸泼尼松龙联合环磷酰胺治疗甲亢突眼的疗效观察[J].医学信息,2014(36):261.

[10]张楠,卢弘.环孢素A在非感染性葡萄膜炎治疗中的应用[J].眼科新进展, 2017,37(3):293-297.

[11]李敏,崔雪娇,李玉铢,等.Graves眼病患者生活质量及眼病特异性生活质量的相关性[J].中国医科大学学报,2016,45(5):445-447,451.

[12]俞丹洋,魏锐利,李玉珍,等.儿童及青少年Graves眼病的临床特点及疗效分析[J].中国实验眼科杂志,2016,34(8):716-719.

[13]Di Tommaso C, Valamanesh F, Miller F, et al. A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. Invest Ophthalmol Vis Sci. 2012;53(4):2292-2299.

[14]Junghanss C, Rathsack S, Wacke R, et al. Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(7):1061-1068.

[15]Afonso M, Perrotti V, Rapani M, et al. Immunoexpression of angiogenesis and proliferation markers in patients treated with cyclosporin A. Minerva Stomatol. 2014;63(3):59-67.

[16]Kim SY, Shim MS, Kim KY, et al. Inhibition of cyclophilin D by cyclosporin A promotes retinal ganglion cell survival by preventing mitochondrial alteration in ischemic injury. Cell Death Dis. 2014;5:e1105.

[17]Fuhrmann A, Lopes P, Sereno J, et al. Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochem Pharmacol. 2014;88(2):216-228.

[18]Cheng M. Hartmann Stahelin (1925-2011) and the contested history of cyclosporin A. Clin Transplant. 2013;27(3):326-329.

[19]Mori M, Inoue D, Arima H, et al. Therapeutic efficacy of cyclosporin A for refractory angioimmunoblastic T cell lymphoma. Rinsho Ketsueki. 2010;51(5):332-338.

[20]Liu H, Wang Y, Han F, et al. Gelatin-stabilised microemulsion-based organogels facilitates percutaneous penetration of Cyclosporin A in vitro and dermal pharmacokinetics in vivo. J Pharm Sci. 2007;96(11): 3000-3009.

[21]刘洪卓.环孢素A皮肤给药系统的设计与评价[D].沈阳:沈阳药科大学,2007.

[22]王黎.中药巴布膏剂的研究概况[J].中华实用中西医杂志, 2007,20(17): 1544-1546.

[23]王雪,高建德.中药巴布剂的研究进展[J].中医儿科杂志, 2007,3(2):54.

[24]庞武耀,李明亚,谢清春.巴布剂的研究现状[J].亚太传统医药, 2008,4(12): 133-136.

[25]宋文娟.接骨巴布膏的制备及临床应用[J].时珍国医国药, 2006,17(11): 2236-2237.

[26]朱庆文,李海燕,杜红.中药经皮给药物理促透技术与发展思路研究[J].国际生物医学工程杂志,2015,38(4):253-256.

[27]冯金鹰.蟾酥巴布膏的研究[D].济南:山东中医药大学,2010.

[28]国家药典委员会.中华人民共和国药典：2000年版.一部[M].北京:化学工业出版社,2000.

[29]刘方艺.经络贴巴布剂的制备工艺与体外经皮渗透研究[D].广州:广州中医药大学,2011.

[30]30梁媛媛,马琳,崔黎丽,等.正极性驻极体和氮酮对环孢素A的体外透皮促渗作用[J].第二军医大学学报,2012,33(6):617-620.

[31]王岚,刘淑芝,王彦礼,等.萸连巴布膏抗消化性溃疡的药效学研究[J].中国实验方剂学杂志,2011,17(7):194-197.

[32]戎宽.肿痛消巴布膏对LDH大鼠TNF-a?IL-1影响的实验研究[D].长沙:湖南中医药大学,2014.

[33]望开鹏.环孢素A纳米粒丝素蛋白-聚乙烯醇共混膜剂的研究[D].苏州:苏州大学,2011.

[34]刘先继,王永强,刘先锋,等.乳癖消巴布膏制备工艺[J].实用中医内科杂志, 2014,28(8):126-127.

[35]徐晖,王绍宁,谷野,等.巴布膏剂研制的一些问题[J].中医外治杂志, 2005, 14(6):3-4.

[36]庞丹梅.万灵五香巴布膏的研制[D].杭州:浙江大学,2005.

[37]Domingo-Chiva E, Ruíz-Ramos J, Marqués-Miñana MR, et al. Drug Interaction Between Oral Cyclosporine Modified and Iron. Ann Pharmacother. 2014;48(7):932-935.

[38]杜茂波.萸连巴布膏的药学研究与评价[D].北京:中国中医科学院,2009.

[39]张韻慧,王春杰,晋兴华,等.吲哚美辛水凝胶贴剂小鼠体外透皮性能研究[J].现代生物医学进展,2013,13(34):6619-6622,6706.

[40]杜丽娜,金义光.经皮给药系统研究进展[J].国际药学研究杂志, 2013, 40(4):379-385.

[41]王海东,倪善红,孙增先.液相色谱-质谱联用和酶增强免疫分析法测定人全血环孢素A浓度比较[J].医药导报, 2016,35(10):1064-1068.

[42]黄培池,王娟.HPLC法测定环孢素滴眼液中环孢素的含量[J].淮海医药, 2015,33(4):382-383.

[43]沙波,齐永贵,叶启发,等.肝肠联合移植后的免疫抑制治疗体会[J].中国器官移植杂志,2000,21(5):283-284.

[44]袁成,王景祥,贾暖,等.兔角膜环孢素A含量测定及其经时过程[J].中国临床药学杂志,1998,7(6):287-290.

[45]周晓庆,张秀华,黄学孙,等.环孢素A滴眼液的制备及治疗控制[J].中国医院药学杂志,2005,25(6):574-575.

[46]王延东,陈茂玲,叶成添,等.环孢素眼用乳剂的制备及质量控制[J].中国实用医药,2010,12 (5):7-9.

[47]陈洁,杨利平,刘春雨,等.高效液相色谱法测定环孢素滴眼液中环孢素的含量[J].药物分析杂志,2006,26(3):372-373.

[48]章元沛.药理学实验[M].2版.北京:人民卫生出版社,1996:222.

[49]胡楠楠,王雪峰,赵雪,等.敷胸巴布贴制剂对健康家兔皮肤刺激实验研究[J].辽宁中医杂志,2012,39(6):1168-1169.

[50]王秋菊,吕娟,张予阳,等.乳癖消巴布膏的刺激性?过敏性及经皮毒性研究[J].药学实践杂志,2008,26(1):31-34.

[51]Garcovich S, Garcovich C, Cassano N, et al. Cyclosporine A microemulsion in dermatological practice: is oral solution better tolerated than soft gelatin capsules? G Ital Dermatol Venereol. 2015;150(4):473-474.

[52]Wendlow SH, Campa E, Harris NL. WHO Classification Tumors of the Haematopoietic and Lymphoid Tissues. Lyon:IARC, Press. 2008:214.

[53]薛彬,张晴,郑占伟,等.HPLC法同时测定环孢素A和其衍生物的含量[J].化学与生物工程,2016,33(3):68-70.

[54]Fruši?-Zlotkin M, Soroka Y, Tivony R, et al. Penetration and biological effects of topically applied cyclosporin A nanoparticles in a human skin organ culture inflammatory model. Exp Dermatol. 2012;21(12): 938-943.